{"id":411424,"date":"2021-01-08T18:51:13","date_gmt":"2021-01-08T23:51:13","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=411424"},"modified":"2021-01-08T18:51:13","modified_gmt":"2021-01-08T23:51:13","slug":"srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\/","title":{"rendered":"SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>, Jan. 8, 2021<\/span> \/PRNewswire\/ —\u00a0Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) resulting from allegations that Sarepta might have issued misleading information to the investing public.<\/p>\n

\n

\n
\n \"Bernstein
\n <\/a>\n <\/p>\n<\/p><\/div>\n

If you purchased Sarepta securities, and\/or would like to discuss your legal rights and options<\/b> please visit SRPT Shareholder Investigation<\/a> or contact Matthew E. Guarnero<\/span><\/a> toll free at (877) 779-1414<\/b> or MGuarnero@bernlieb.com<\/a>. <\/p>\n

On January 7, 2021<\/span>, after market hours, Sarepta announced its “top-line results for Part 1 of Study 102 evaluating SRP-9001, its investigational gene therapy for the treatment of Duchenne muscular dystrophy.” According to Sarepta, “the study did not achieve statistical significance on the primary functional endpoint of improvement [\u2026] compared to placebo at 48 weeks post-treatment[.]”<\/p>\n

On this news, Sarepta’s shares are trading at approximately $82.00<\/span> per share, down over 50%, on January 8, 2021<\/span>.<\/p>\n

If you purchased<\/b>Sarepta securities, and\/or would like to discuss your legal rights and options<\/b> please visit https:\/\/www.bernlieb.com\/cases\/sareptatherapeuticsinc-srpt-shareholder-class-action-lawsuit-stock-fraud-354\/apply\/<\/a>Matthew E. Guarnero<\/span><\/a> toll free at (877) 779-1414<\/b> or MGuarnero@bernlieb.com<\/a>. <\/p>\n

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion<\/span> for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.<\/p>\n

ATTORNEY ADVERTISING. \u00a9 2021 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York<\/span> 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut<\/span> is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.<\/p>\n

Contact Information<\/p>\n

\n Matthew E. Guarnero<\/span>
\n
Bernstein Liebhard LLP
https:\/\/www.bernlieb.com<\/a>
(877) 779-1414
MGuarnero@bernlieb.com<\/a><\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws-301203624.html<\/a><\/p>\n

SOURCE Bernstein Liebhard LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK, Jan. 8, 2021 \/PRNewswire\/ —\u00a0Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) resulting from allegations that Sarepta might have issued misleading information to the investing public. If you purchased Sarepta securities, and\/or would like to discuss your legal rights and options please visit SRPT Shareholder Investigation or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com. On January 7, 2021, after market hours, Sarepta announced its “top-line results for Part 1 of Study 102 evaluating SRP-9001, its investigational gene therapy for the treatment of Duchenne muscular dystrophy.” According to Sarepta, “the study did … <\/p>\n

Continue reading “SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-411424","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Jan. 8, 2021 \/PRNewswire\/ —\u00a0Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) resulting from allegations that Sarepta might have issued misleading information to the investing public. If you purchased Sarepta securities, and\/or would like to discuss your legal rights and options please visit SRPT Shareholder Investigation or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com. On January 7, 2021, after market hours, Sarepta announced its “top-line results for Part 1 of Study 102 evaluating SRP-9001, its investigational gene therapy for the treatment of Duchenne muscular dystrophy.” According to Sarepta, “the study did … Continue reading "SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-08T23:51:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/616919\/Bernstein_Liebhard_LLP_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws\",\"datePublished\":\"2021-01-08T23:51:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\\\/\"},\"wordCount\":371,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/616919\\\/Bernstein_Liebhard_LLP_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\\\/\",\"name\":\"SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/616919\\\/Bernstein_Liebhard_LLP_Logo.jpg\",\"datePublished\":\"2021-01-08T23:51:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/616919\\\/Bernstein_Liebhard_LLP_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/616919\\\/Bernstein_Liebhard_LLP_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\/","og_locale":"en_US","og_type":"article","og_title":"SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws - Market Newsdesk","og_description":"PR Newswire NEW YORK, Jan. 8, 2021 \/PRNewswire\/ —\u00a0Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) resulting from allegations that Sarepta might have issued misleading information to the investing public. If you purchased Sarepta securities, and\/or would like to discuss your legal rights and options please visit SRPT Shareholder Investigation or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com. On January 7, 2021, after market hours, Sarepta announced its “top-line results for Part 1 of Study 102 evaluating SRP-9001, its investigational gene therapy for the treatment of Duchenne muscular dystrophy.” According to Sarepta, “the study did … Continue reading \"SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-08T23:51:13+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/616919\/Bernstein_Liebhard_LLP_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws","datePublished":"2021-01-08T23:51:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\/"},"wordCount":371,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/616919\/Bernstein_Liebhard_LLP_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\/","name":"SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/616919\/Bernstein_Liebhard_LLP_Logo.jpg","datePublished":"2021-01-08T23:51:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/616919\/Bernstein_Liebhard_LLP_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/616919\/Bernstein_Liebhard_LLP_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/srpt-investigation-alert-bernstein-liebhard-is-investigating-sarepta-therapeutics-inc-for-violations-of-the-securities-laws\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=411424"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411424\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=411424"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=411424"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=411424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}